Present Investigation of this experiment are aimed primarily the avoidance of hepatic first pass metabolism and to improve therapeutic efficacy for the treatment of Parkinson’s disease. To achieve the goal nine formulations (N1-N9) of NLCs were fabricated by high speed homogenization technique and optimize by 32 full factorial designs. The design was validated by extra design check point formulation (N10) and responses were analyzed using Design Expert software 11. The NLCs were evaluated for particle size, polydispersity index (PDI), % entrapment efficiency, in vitro, ex-vivo drug diffusion and histopathological studies. Differential Scanning Calorimetry (DSC) analysis revealed the encapsulation of amorphous form of drug into lipid matrix, while scanning electron microscopy studies indicated the smooth surface. The Fabricated NLCs had a mean particle size of 143.0 nm with narrow size distribution (PDI – 0.178), entrapment efficiency (% EE - 86.42 ± 1.410), and % control drug release (%CDR-91.37± 1.395). Histopathological study showed intact nasal mucosa with no severe signs of damage as compared to drug alone. Results of analysis of variance demonstrated the significance of suggested model. These results clearly provide a lead that above ROPI-NLCs is a potential nanoparticle formulation and could be a promising drug delivery system of Parkinson’s.

Ropinirole, Nano structure lipid carriers, Factorial design, Histopathology study